Pamela Ritchey
Acute Care · Birmingham, ALNPI 1881612216
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 148 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,342 and has fallen 95.7% since, to $57 in 2025.
Across 148 payments — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$568
- E.r. Squibb & Sons, L.L.C.$384
- Amgen$213
- AstraZeneca$167
- Merck$119
- Pfizer$111
- plus $1K from 28 others
What the payments were for
- Food & beverage$2,667100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 32 | $568 |
| E.r. Squibb & Sons, L.L.C. | 19 | $384 |
| Amgen | 11 | $213 |
| AstraZeneca | 11 | $167 |
| Merck | 6 | $119 |
| Pfizer | 7 | $111 |
| Seagen Inc. | 6 | $100 |
| Regeneron Healthcare Solutions, Inc. | 5 | $83 |
| Daiichi Sankyo Inc. | 4 | $78 |
| Bristol Myers Squibb | 5 | $74 |
| AbbVie | 3 | $67 |
| Eisai Inc. | 4 | $66 |
| Lilly USA, LLC | 3 | $52 |
| Gilead(2 entities) | 3 | $51 |
| Deciphera Pharmaceuticals Inc. | 3 | $47 |
| Tempus AI, Inc | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $46 |
| Pharmacosmos Therapeutics Inc. | 2 | $37 |
| Incyte Corporation | 2 | $31 |
| Exelixis Inc. | 2 | $31 |
| Johnson & Johnson | 1 | $30 |
| Myovant Sciences Inc. | 2 | $30 |
| Jazz Pharmaceuticals Inc. | 2 | $29 |
| Puma Biotechnology, Inc. | 1 | $27 |
| AMAG Pharmaceuticals, Inc. | 1 | $26 |
| Array Biopharma Inc | 1 | $24 |
| Blueprint Medicines Corporation | 1 | $24 |
| Karyopharm Therapeutics Inc. | 1 | $21 |
| Sanofi | 1 | $19 |
| Acrotech Biopharma Inc. | 1 | $17 |
| Pulmonx Corporation | 1 | $16 |
| Coherus Oncology, Inc. | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Clovis Oncology, Inc. | 1 | $14 |
How this compares
$2,680 in reported general payments places this provider in the 80th percentile of 711 acute care providers in Alabama.
Other acute care in Birmingham
- Coretta CollinsBirmingham$77K
- Cameron StephensonBirmingham$13K
- Jonathan McCraryBirmingham$13K
- Michelle PriceBirmingham$13K
- Melissa FrenchBirmingham$13K
- Jaime CannonBirmingham$12K
- Kaci WeaverBirmingham$11K
- Alexandra GlennBirmingham$11K
- Bridget CrainBirmingham$10K
- Rachel CookBirmingham$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.